Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bimatoprost + latanoprost is a combination of two prostaglandin analogs, both used as ophthalmic agents to lower intraocular pressure (IOP) in conditions such as primary open-angle glaucoma and ocular hypertension. Both drugs act primarily by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby reducing IOP. Bimatoprost is a synthetic prostamide analog, while latanoprost is a prostaglandin F2α analog. Although each drug individually lowers IOP effectively, clinical studies have shown that their concurrent use does not provide an additive benefit and may paradoxically increase IOP or reduce the efficacy of either agent when combined. Therefore, this combination is generally not recommended for therapeutic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bimatoprost + latanoprost.